First Things First: Navigating ALK-Positive Metastatic Non-Small Cell Lung Cancer Treatment Options—A Podcast

The podcast discusses the available treatment options for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) and focuses on the efficacy and safety of first-line treatments and sequencing strategies. Patients with ALK-positive NSCLC often need multiple lines of therapy owing to the development of resistance, disease progression, brain metastases, or adverse events. Several options are available for the treatment of ALK-positive NSCLC; therefore, it is important to make an informed decision on which treatment to use in the first line. The podcast also discusses the challenges in treatment sequencing due to high attrition rates from first-line to second-line therapy and the decline in treatment efficacy with each additional line. Real-world data indicate that many patients do not receive second-line therapy after discontinuing first-line treatment. The discussion emphasizes the importance of consideration of drug efficacy, safety outcomes, potential treatment resistance, and development of brain metastases when determining treatment strategies. Ultimately, it is essential to select the best treatment first and proactively manage any potential adverse events to ensure that patients can derive clinical benefit and safely remain on therapy.